Last $154.87 USD
Change Today -1.13 / -0.72%
Volume 357.9K
ICPT On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

intercept pharmaceuticals in (ICPT) Snapshot

Open
$158.33
Previous Close
$156.00
Day High
$158.70
Day Low
$154.10
52 Week High
01/10/14 - $497.00
52 Week Low
11/25/13 - $50.03
Market Cap
3.3B
Average Volume 10 Days
708.3K
EPS TTM
$-16.60
Shares Outstanding
21.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTERCEPT PHARMACEUTICALS IN (ICPT)

intercept pharmaceuticals in (ICPT) Related Businessweek News

No Related Businessweek News Found

intercept pharmaceuticals in (ICPT) Details

Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing its proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trial to treat portal hypertension; in Phase II clinical trial for the treatment of alcoholic hepatitis; in Phase IIb clinical trial for the treatment of nonalcoholic steatohepatitis; and in Phase IIa clinical trial to treat bile acid diarrhea. The company was founded in 2002 and is headquartered in New York, New York.

122 Employees
Last Reported Date: 11/6/14
Founded in 2002

intercept pharmaceuticals in (ICPT) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $934.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $556.9K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $626.5K
Compensation as of Fiscal Year 2013.

intercept pharmaceuticals in (ICPT) Key Developments

Intercept Pharmaceuticals, Inc. Announces Additional Data for OCA in Primary Biliary Cirrhosis

Intercept Pharmaceuticals, Inc. announced new analyses of data from clinical trials on obeticholic acid (OCA) in patients with primary biliary cirrhosis (PBC). Six posters, including posters with new analyses of data from POISE -- the first Phase 3 trial in PBC in two decades -- are being presented at today's poster session at the American Association for the Study of Liver Disease (AASLD) Annual Meeting. OCA, Intercept's lead product candidate, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR) in development for PBC, nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and other chronic liver diseases. In March 2014, Intercept announced that OCA met the primary endpoint of the POISE trial with high statistical significance (p < 0.0001). The posters to be presented at AASLD provide the following information relating to OCA in PBC: Poster 318 provides new subgroup analyses of the treatment effect for OCA across a range of patient characteristics associated with greater risk of adverse clinical outcomes, including age at diagnosis, duration of PBC and baseline alkaline phosphatase (ALP); Poster 295 presents analyses on the effects of OCA treatment versus placebo on markers of cholestasis (ALP, bilirubin) and hepatobiliary damage (GGT, AST, and ALT), as well as markers of inflammation (C-reactive protein or CRP) and apoptosis (cytokeratin-18 or CK-18); Poster 309 presents POISE results in relation to the proportion of patients achieving a response defined by different response criteria, other than the POISE endpoint, such as Paris I, Paris II and Rotterdam; Posters 305 and 310 cover new information relating to the titration arm of POISE, where approximately half the patients in the titration arm had their OCA dose increased from 5 mg to 10 mg after six months of treatment based on clinical response. These posters present new data regarding the potential utility of titration as a dosing strategy in the context of managing pruritus, the primary tolerability issue of OCA treatment, while investigating the effects of titration on the efficacy of OCA treatment; Poster 319 describes the long-term safety and efficacy results from open-label treatment of OCA for over four years as part of the long-term safety extension trial on patients who participated in a Phase 2 PBC trial that evaluated OCA monotherapy.

Intercept Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Intercept Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company's net loss $35.84 million, or $1.69 per share, compared to $31.7 million, or $1.65 per share, for the same period in 2013. Included in the net loss non-cash charges related to the periodic revaluation of warrant liability of $0 and $20.8 million and non-cash share-based compensation of $5.2 million and $3.0 million in each of the three month periods ended September 30, 2014 and 2013, respectively. Licensing revenue was $405,000 against $405,000 a year ago. For the nine months, the company's net loss was $248.40 million, or $12.07 per share, compared to $55.4 million, or $3.15 per share, for the nine months ended September 30, 2013. Included in the net loss non-cash charges related to the periodic revaluation of warrant liability of $170.8 million and $30.0 million and non-cash share-based compensation of $16.5 million and $6.5 million in each of the nine month periods ended September 30, 2014 and 2013, respectively. Licensing revenue was $1.30 million for the nine months ended September 30, 2014, compared to $1.2 million for the corresponding period of the prior year.

Intercept Pharmaceuticals, Inc. - Special Call

To provide FLINT Update

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICPT:US $154.87 USD -1.13

ICPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ICPT.
View Industry Companies
 

Industry Analysis

ICPT

Industry Average

Valuation ICPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,935.0x
Price/Book 12.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,783.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTERCEPT PHARMACEUTICALS IN, please visit www.interceptpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.